Daily Bulletin

Men's Weekly

.

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
  • Phase 2 study of PVX108 to commence in United States and Australia
  • Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board

MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...

Read more: Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation...

Business News

Manhari Founder, Maddy Gupta, urges businesses to capitalise on the rising value of metals

Old and unwanted equipment and business assets are often worth far more than they appear particularly those containing valuable metals. Precious metals, led by gold and silver reaching record highs...

Daily Bulletin - avatar Daily Bulletin

Qualities to Check in an NDIS Provider

Everyone wants to live life with independence and dignity. For people with disabilities, achieving this often requires the right support. This is where NDIS providers play an important role. These pro...

Daily Bulletin - avatar Daily Bulletin

How Thorough Component Inspections Protect Your Supply Chain from Costly Failures

In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business